Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Nov 28:9:64-65.
doi: 10.18632/oncoscience.568. eCollection 2022.

Ikaros as a downstream mediator of BCR blockade therapy in B-cell non-Hodgkin lymphoma

Marcelo Lima Ribeiro, Emmanuel Normant, Gaël Roué
Editorial

Ikaros as a downstream mediator of BCR blockade therapy in B-cell non-Hodgkin lymphoma

Marcelo Lima Ribeiro et al. Oncoscience. .
No abstract available

Keywords: B-NHL; Bruton’s tyrosine kinase; Ikaros; combination therapies; phosphoproteomics.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1. Early clinical response to the selective BTK inhibitor TG-1701 relies on the disruption of Ikaros transcriptional program.
See this image and copyright information in PMC

References

    1. Kraus M, et al.. Cell. 2004; 117:787–800. 10.1016/j.cell.2004.05.014. - DOI - PubMed
    1. Küppers R, et al.. Nat Rev Cancer. 2005; 5:251–62. 10.1038/nrc1589. - DOI - PubMed
    1. Honigberg LA, et al.. Proc Natl Acad Sci U S A. 2010; 107:13075–80. 10.1073/pnas.1004594107. - DOI - PMC - PubMed
    1. Xue C, et al.. Cancer Cell Int. 2020; 20:467. 10.1186/s12935-020-01518-y. - DOI - PMC - PubMed
    1. Profitós-Pelejà N, et al.. Cancers (Basel). 2022; 14:860. 10.3390/cancers14040860. - DOI - PMC - PubMed

Publication types

LinkOut - more resources